Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2020 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Participation in Two Upcoming Virtual Conferences

SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, Daré’s President and CEO,...
September 01, 2020 08:04 ET | Source: Daré Bioscience, Inc.

Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs

SAN DIEGO and ANN ARBOR, Mich., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Avomeen, an accredited, independent contract...
August 20, 2020 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Publication of DARE-BV1 Proof of Concept Study for the Treatment of Bacterial Vaginosis

SAN DIEGO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the publication of a proof of concept study of DARE-BV1 in...
August 19, 2020 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-FRT1 Phase 1 Human Clinical Study for the Prevention of Preterm Birth

SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it received a Notice of Award of a grant from the...
August 12, 2020 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Reports Second Quarter 2020 Financial Results and Provides Company Update

SAN DIEGO, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the second quarter ended June 30, 2020...
August 06, 2020 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience CEO to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference

SAN DIEGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive...
August 05, 2020 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience to Host Second Quarter 2020 Financial Results and Company Update Conference Call and Webcast on August 12, 2020

SAN DIEGO, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
July 27, 2020 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Initiation of Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy for the Treatment of Menopausal Symptoms

SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the initiation of a Phase 1 clinical trial of DARE-HRT1. ...
June 24, 2020 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Publication of a Peer-Reviewed Journal Article Supporting the Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction

Includes positive clinical findings from a postcoital test (PCT) human clinical study of Ovaprene®, an investigational hormone-free, monthly contraceptive SAN DIEGO, June 24, 2020 (GLOBE NEWSWIRE)...
June 17, 2020 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis

SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the initiation of the DARE-BVFREE study, a multi-center,...